{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:34:12Z","timestamp":1792056852078,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102153","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:35:27Z","timestamp":1778067327000},"page":"102153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7865-8421","authenticated-orcid":false,"given":"Malika","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Vundamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102153_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.berh.2026.102153_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.15585\/mmwr.mm6818a4","article-title":"Racial disparities in mortality associated with systemic lupus Erythematosus - fulton and DeKalb counties, Georgia, 2002-2016","volume":"68","author":"Lim","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.berh.2026.102153_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.berh.2026.102153_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on Lupus Nephritis: Core Curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.berh.2026.102153_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102153_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3899\/jrheum.191094","article-title":"Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis","volume":"48","author":"Petri","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-025-00653-y","article-title":"Lupus nephritis","volume":"11","author":"Parodis","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.berh.2026.102153_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/acr.22562","article-title":"Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to Lupus nephritis","volume":"67","author":"G\u00f3mez-Puerta","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102153_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/art.38220","article-title":"End-stage renal disease in African Americans with lupus nephritis is associated with APOL1","volume":"66","author":"Freedman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib13","first-page":"2024","article-title":"Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis","volume":"34","author":"Ward","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib14","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.091199","article-title":"Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus","volume":"37","author":"Ward","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"American College of Rheumatology (ACR) Guideline for the screening, treatment, and management of Lupus nephritis","volume":"77","author":"Sammaritano","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102153_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2026.102153_bib17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib18","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102153_bib19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.berh.2026.102153_bib20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib21","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102153_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102153_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2026.102153_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib26","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102153_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2026.102153_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of Rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib32","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib33","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102153_bib34","article-title":"Comparing the impact of GLP-1 Agonists and SGLT-2 inhibitors on outcomes in lupus nephritis: a retrospective cohort study [abstract]","volume":"77","author":"Grzybowski","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103422","article-title":"Is per-protocol kidney biopsy required in lupus nephritis?","volume":"23","author":"Parodis","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102153_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2026.102153_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2026.102153_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000721","article-title":"Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis","volume":"9","author":"Moroni","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"supp 9","key":"10.1016\/j.berh.2026.102153_bib39","article-title":"Redefining when to biopsy the kidney in patients with SLE","volume":"77","author":"Petri","year":"2025","journal-title":"ACR Meeting Abstracts"},{"key":"10.1016\/j.berh.2026.102153_bib40","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2215\/CJN.04710420","article-title":"Systematic review and meta-analysis of native Kidney Biopsy Complications","volume":"15","author":"Poggio","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.berh.2026.102153_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ndt\/gfac177","article-title":"The risks associated with percutaneous native kidney biopsies: a prospective study","volume":"38","author":"Andrulli","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2026.102153_bib42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2026.102153_bib43","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","article-title":"Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102153_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib45","article-title":"Per-protocol repeat kidney Biopsy in Systemic Lupus Erythematosus (SLE). Lupus Nephritis (LN)","author":"Parodis","year":"2025","journal-title":"Karolinska Institutet"},{"key":"10.1016\/j.berh.2026.102153_bib46","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/life15101497","article-title":"Biomarkers in lupus nephritis: an evidence-based comprehensive review","volume":"15","author":"Vrabie","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.berh.2026.102153_bib47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.42941","article-title":"Association of autoantibody concentrations and trajectories with Lupus Nephritis histologic features and treatment response","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-025-03536-5","article-title":"Clinical and immunological biomarkers can identify proliferative changes and predict renal flares in lupus nephritis","volume":"27","author":"Calatroni","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102153_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/rheumatology\/keu343","article-title":"Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus","volume":"54","author":"Ishizaki","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102153_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1655825","article-title":"Isolated C3 hypocomplementemia as an early predictor of chronic kidney disease in lupus nephritis","volume":"16","author":"Andrulli","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2019121285","article-title":"Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis","volume":"31","author":"Mejia-Vilet","year":"2020","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.berh.2026.102153_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185x.70470","article-title":"Predictive factors for renal outcome during remission induction treatment period in lupus nephritis","volume":"28","author":"Kamada","year":"2025","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2026.102153_bib53","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib54","article-title":"Low-Grade proteinuria does not predict favorable outcomes in lupus nephritis: a longitudinal cohort Study","author":"Shen","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102153_bib55","article-title":"Urinary Tenascin C predicts kidney function loss in lupus nephritis [abstract]","volume":"77","author":"Lee","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib56","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/acr.25652","article-title":"Serum soluble mediator signatures of lupus nephritis: histologic features and response to treatment","volume":"78","author":"Fava","year":"2026","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102153_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181034","article-title":"Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis","volume":"135","author":"Horisberger","year":"2025","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102153_bib58","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2024.09.007","article-title":"Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts","volume":"106","author":"Vodehnal","year":"2024","journal-title":"Kidney Int"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102153_bib59","article-title":"Urinary biomarkers detect proliferative lupus nephritis in SLE patients with subclinical proteinuria. [abstract]","volume":"77","author":"Lee","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172569","article-title":"Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis","volume":"9","author":"Fava","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.berh.2026.102153_bib61","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10067-020-05454-0","article-title":"Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis","volume":"40","author":"Urrego-Callejas","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.42023","article-title":"Urine proteomics and renal single cell transcriptomics implicate IL-16 in Lupus nephritis","volume":"74","author":"Fava","year":"2022","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.berh.2026.102153_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaut.2006.12.003","article-title":"Urinary TWEAK and the activity of lupus nephritis","volume":"27","author":"Schwartz","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.berh.2026.102153_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/ar2816","article-title":"Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study","volume":"11","author":"Schwartz","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102153_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323334","article-title":"Urinary MCP-1 and VCAM-1 as non-invasive biomarkers for the diagnosis and activity assessment of lupus nephritis","volume":"20","author":"Lai","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2026.102153_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83057-4","article-title":"Exploring potential multiple molecular biomarkers that predict treatment response in patients with lupus nephritis","volume":"14","author":"Park","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102153_bib67","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.berh.2026.102153_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.berh.2026.102153_bib69","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene Pathway Co-Expression patterns: a Double-Blind, randomized, Placebo-Controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib70","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03724-3","article-title":"A BAFF\/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study","author":"Wei","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102153_bib72","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102153_bib73","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric Antigen Receptor\u2013T cells in the treatment of chronic autoimmune rheumatic diseases?","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib74","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib75","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102153_bib76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease \u2014 a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102153_bib77","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2025-0390.PV250","article-title":"Potent and specific killing of Sle B cells with allonk\u00ae (ab-101), an allogeneic cord Blood-Nk cell therapy, in combination with Anti-Cd19 or Anti-Cd20 monoclonal antibodies","volume":"52","author":"Rogers","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib78","doi-asserted-by":"crossref","first-page":"4846.1","DOI":"10.1182\/blood-2024-212347","article-title":"A phase 1 Study of NKX019, an allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapy in patients with systemic lupus erythematosus","volume":"144","author":"Askanase","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.berh.2026.102153_bib79","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic Human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cells9030768","article-title":"NK cells and CD38: implication for (Immuno)Therapy in Plasma Cell Dyscrasias","volume":"9","author":"Zambello","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.berh.2026.102153_bib81","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102153_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102668","article-title":"Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis","volume":"19","author":"Ramanujam","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102153_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202200925","article-title":"Engineered cell membrane vesicles expressing CD40 alleviate System lupus nephritis by intervening B cell activation","volume":"7","author":"Fang","year":"2023","journal-title":"Small Methods"},{"key":"10.1016\/j.berh.2026.102153_bib84","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/art.42557","article-title":"Clinical and biomarker responses to BI 655064, an antagonistic Anti-CD40 antibody, in patients with active lupus nephritis: a randomized, Double-Blind, Placebo-Controlled, phase II trial","volume":"75","author":"Jayne","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib85","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/art.43076","article-title":"Outcome of patients with Lupus Nephritis treated with an Anti-CD40 monoclonal antibody according to Kidney Biopsy features","volume":"77","author":"Uzzo","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ard.2025.05.213","article-title":"OP0201 achievement of low disease activity and remission in patients with systemic lupus erythematosus treated with dapirolizumab pegol: 48-WEEK results from a phase 3 trial","volume":"84","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000431278","article-title":"Complement in lupus nephritis: new perspectives","volume":"1","author":"Bao","year":"2015","journal-title":"Kidney Dis"},{"key":"10.1016\/j.berh.2026.102153_bib88","first-page":"418","article-title":"Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody","volume":"25","author":"Cameron","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib89","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/jcm10040626","article-title":"Expanding the role of complement therapies: the case for lupus nephritis","volume":"10","author":"Li","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.berh.2026.102153_bib90","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of Pegcetacoplan in a phase 2 Study of patients with C3 Glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.berh.2026.102153_bib91","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ekir.2023.02.147","article-title":"WCN23-0405 an adaptive, dose-exploration, phase 2 trial evaluating efficacy and safety of iptacopan in combination with standard-of-care with and without oral corticosteroids in active lupus nephritis","volume":"8","author":"Veldandi","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.berh.2026.102153_bib92","unstructured":"Study of efficacy and safety of LNP023 in participants with active lupus nephritis class III-IV, +\/- V. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05268289. ClinicalTrials.gov identifier: NCT05268289."},{"key":"10.1016\/j.berh.2026.102153_bib93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.clim.2018.10.008","article-title":"BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115297","article-title":"Blockade of Bruton's tyrosine kinase suppresses B cell activation and antibody secretion in systemic lupus erythematosus","volume":"163","author":"Shi","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102153_bib95","article-title":"Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis [abstract]","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - Association to histopathology and response to treatment","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol"},{"key":"10.1016\/j.berh.2026.102153_bib97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jir.2018.0016","article-title":"Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus","volume":"39","author":"Shao","year":"2019","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"10.1016\/j.berh.2026.102153_bib98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102153_bib99","doi-asserted-by":"crossref","first-page":"keaf536","DOI":"10.1093\/rheumatology\/keaf536","article-title":"Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study","volume":"65","author":"Zhao","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102153_bib100","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/rheumatology\/keae647","article-title":"Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study","volume":"64","author":"Anders","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102153_bib101","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00296-023-05389-0","article-title":"Experience with abatacept in refractory lupus nephritis","volume":"43","author":"Calatayud","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2026.102153_bib102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a Twelve-Month, randomized, double-blind Study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102153_bib103","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2023-eular.2317","article-title":"Pos1128 Zetomipzomib (kzr-616) treatment results in clinically meaningful renal responses in patients with lupus nephritis","volume":"82","author":"Saxena","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:38:36Z","timestamp":1789112316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000380"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102153","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102153"}}